Cargando…

Visualizing GABA transporters in vivo: an overview of reported radioligands and future directions

By clearing GABA from the synaptic cleft, GABA transporters (GATs) play an essential role in inhibitory neurotransmission. Consequently, in vivo visualization of GATs can be a valuable diagnostic tool and biomarker for various psychiatric and neurological disorders. Not surprisingly, in recent years...

Descripción completa

Detalles Bibliográficos
Autores principales: Knippenberg, Niels, Bauwens, Matthias, Schijns, Olaf, Hoogland, Govert, Florea, Alexandru, Rijkers, Kim, Cleij, Thomas J., Eersels, Kasper, van Grinsven, Bart, Diliën, Hanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182260/
https://www.ncbi.nlm.nih.gov/pubmed/37171631
http://dx.doi.org/10.1186/s13550-023-00992-5
Descripción
Sumario:By clearing GABA from the synaptic cleft, GABA transporters (GATs) play an essential role in inhibitory neurotransmission. Consequently, in vivo visualization of GATs can be a valuable diagnostic tool and biomarker for various psychiatric and neurological disorders. Not surprisingly, in recent years several research attempts to develop a radioligand have been conducted, but so far none have led to suitable radioligands that allow imaging of GATs. Here, we provide an overview of the radioligands that were developed with a focus on GAT1, since this is the most abundant transporter and most of the research concerns this GAT subtype. Initially, we focus on the field of GAT1 inhibitors, after which we discuss the development of GAT1 radioligands based on these inhibitors. We hypothesize that the radioligands developed so far have been unsuccessful due to the zwitterionic nature of their nipecotic acid moiety. To overcome this problem, the use of non-classical GAT inhibitors as basis for GAT1 radioligands or the use of carboxylic acid bioisosteres may be considered. As the latter structural modification has already been used in the field of GAT1 inhibitors, this option seems particularly viable and could lead to the development of more successful GAT1 radioligands in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13550-023-00992-5.